BridgeBio Pharma's fair value estimate has nudged higher to roughly $84.65 per share, as analysts bake in slightly stronger revenue growth assumptions of about 80.8% driven by better than expected ...

Big tech and AI remain dominant market drivers, but energy sector capex is growing to meet rising demand. Read what this all ...

As the U.S. stock market experiences a surge following the Federal Reserve's decision to cut interest rates, major indices like the S&P 500 and Dow Jones Industrial Average are nearing record highs, ...

Wall Street analysts appear to be highly disappointed by software giant Oracle’s ($ORCL) mixed Q2FY26 results and weak ...

ORCL slides 11% as Q2 revenues miss forecasts, cloud momentum clashes with soaring CapEx and weak software demand, leaving ...

After climbing 167% in 2023 and 340% in 2024, Palantir ( PLTR 0.20%) stock is on course to deliver another stellar return in ...

Celestica (CLS) stock analysis: recent growth may be overvalued amid high P/E and slowing data center spending. Read here for ...

The company's underlying operational performance remains robust. Its third-quarter results were record-setting, with revenue reaching $9.25 billion—a 36% year-over-year increase. The data center ...

Advanced Micro Devices (AMD) has been on an extraordinary run lately, with shares soaring 116% as enthusiasm around AI ...

AMD stock delivered stronger returns than Nvidia in 2025, and the stock can still be bought at a cheaper valuation. AMD ...

Advanced Micro Devices (AMD) has launched a sweeping strategic initiative, unveiling several major partnerships and investments worth billions of dollars in ...

HSBC forecasts a massive $207B funding gap for OpenAI's expansion plans, raising questions about future growth ...